Author:
Kim Hyery,Kang Hyoung Jin,Lee Ji Won,Park June Dong,Park Kyung Duk,Shin Hee Young,Ahn Hyo Seop
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Medicine,Pediatrics, Perinatology and Child Health
Reference36 articles.
1. Abigerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13(1):210–221
2. Aguilera D, Mazewski C, Fangusaro J, Macdonald TJ, McNall-Knapp RY, Hayes LL, Kim S, Castellino RC (2013) Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Child's nervous system: ChNS: official journal of the International Society for Pediatric Neurosurgery 29(4):589–596. doi: 10.1007/s00381-012-2013-4
3. Arbuck SG, Takimoto CH (1998) An overview of topoisomerase I-targeting agents. Semin Hematol 35(3 Suppl 4):3–12
4. Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, Longee D (1996) Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 14(6):1922–1927
5. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M (2001) A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 7(1):32–37
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献